Seattle Genetics Inc (SGEN)

neg -1.55
Today's Range: 62.81 - 66.59 | SGEN Avg Daily Volume: 1,213,700
Last Update: 12/07/16 - 4:00 PM EST
Volume: 1,008,029
YTD Performance: 45.03%
Open: $65.45
Previous Close: $66.64
52 Week Range: $26.02 - $50.67
Oustanding Shares: 141,552,646
Market Cap: 9,433,068,329
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 4 4 4
Moderate Buy 2 2 2 2
Hold 7 6 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.29 2.13 2.13 2.05
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -85.44
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-85.44 0.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
32.19% 67.33% 46.76%
Revenue 17.50 0.60 0.17
Net Income 0.00 1.20 0.00
EPS 0.00 1.00 0.00
Earnings for SGEN:
Revenue 0.34B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $-0.34 $-0.27 $-0.94 $-0.88
Number of Analysts 7 2 8 7
High Estimate $-0.24 $-0.25 $-0.85 $-0.40
Low Estimate $-0.38 $-0.28 $-0.99 $-1.34
Prior Year $-0.18 $-0.15 $-0.93 $-0.94
Growth Rate (Year over Year) -88.10% -76.67% -1.48% 7.21%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Sep 15, 2016 | 7:08 AM EDT
SGEN was upgraded from Sell to Neutral, Goldman Sachs said. $47 price target. Expect greater market penetration for Adcetris.
Jul 27, 2016 | 7:28 AM EDT
SGEN was downgraded to Hold, Cantor Fitzgerald said. Buy rating, based on a $43 price target.
Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.
Feb 10, 2016 | 7:36 AM EST
SGEN was upgraded to Buy, Cantor Fitzgerald said. $38 price target. Guidance for Adcetris is likely too conservative.
This biotech is not as high-risk a play as you might think.  
The trade is once again the out-of-the-money, bullishly biased vertical call spread.
Oct 31, 2014 | 7:01 AM EDT
SGEN was upgraded from Sell to Hold, Cantor Fitzgerald said. $35 price target. Company has improved pipeline visibility. 
Sep 30, 2014 | 7:42 AM EDT
SGEN was downgraded form Neutral to Underperform, Bank of America/Merrill Lynch said. $34 price target. Aethera data was not as positiv...
A HERO may still emerge.
Become more aggressive about the real valuations of companies.

Columnist Conversations

The great Skip Raschke joins me after the close to talk options, trading and other stuff he has learned over a...
Big day for TWTR.  The stock is up over 6% with the help of a nice bump in volume.  It still has a b...
Shares of Weyerhaeuser (WY) are breaking above five month horizontal resistance and making a new 52 week high...
This stock is having a strong day with great volume, good flow lately (Feb 140 strikes) and a potential breako...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.